ZBHNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
ZIMMER BIOMET HOLDINGS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$94.99+0.01 (+0.01%)
Close on Oct 19, 2026
- Market cap
- $18.31B
- P/E (TTM)
- 23.1
- Dividend yield
- 1.01%
ZIMMER BIOMET HOLDINGS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Knees [Member] | $828.90M | $828.60M | $911.10M | $792.40M | $826.00M | $792.90M | $839.20M | $745.10M | $801.10M | $788.10M | $798.30M | $706.30M | 38.1% | +0.4% |
| S.E.T [Member] | $586.00M | $562.20M | $587.60M | $541.50M | $550.60M | $470.50M | $489.30M | $454.20M | $469.50M | $452.60M | $453.30M | $423.20M | 26.9% | +6.4% |
| Hips [Member] | $562.70M | $524.10M | $555.40M | $506.20M | $536.10M | $495.80M | $520.00M | $481.50M | $506.50M | $491.20M | $504.70M | $465.30M | 25.8% | +5.0% |
| Technology & Data, Bone Cement and Surgical [Member] | $199.40M | $171.80M | $189.70M | $161.30M | $164.60M | $149.90M | $174.70M | $143.40M | $164.90M | $157.30M | – | – | 9.2% | +21.1% |
| Other [Member] | – | – | – | – | – | – | – | $143.40M | $164.90M | $157.30M | $183.80M | $158.80M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas [Member] | $1.36B | $1.32B | $1.41B | $1.25B | $1.29B | $1.21B | $1.27B | $1.14B | $1.20B | $1.19B | $1.21B | $1.11B | 62.4% | +5.6% |
| United States | $1.24B | $1.21B | $1.31B | $1.16B | $1.17B | $1.11B | $1.18B | $1.05B | $1.11B | $1.10B | $1.13B | $1.03B | 57.0% | +5.6% |
| International [Member] | $937.00M | $877.40M | – | $837.30M | $903.50M | $795.50M | $841.90M | $771.90M | $835.80M | $790.00M | $811.90M | $722.20M | 43.0% | +3.7% |
| EMEA [Member] | $478.50M | $489.90M | $501.30M | $417.00M | $458.10M | $441.70M | $437.70M | $376.20M | $432.40M | $444.80M | $426.00M | $337.90M | 22.0% | +4.5% |
| Asia Pacific [Member] | $339.50M | $272.30M | $329.40M | $330.90M | $332.20M | $260.50M | $312.50M | $312.00M | $310.30M | $258.00M | $301.00M | $302.10M | 15.6% | +2.2% |
From the segment and revenue-disaggregation notes of Zimmer Biomet's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.